News

White-Out-Cancer campaign of Cancer Research Institute inspires support 06.06.2014

On June 6, institutes, companies and citizens around the world are showing their commitment and support for cancer immunotherapy in a campaign initiated by the Cancer Research Institute of New York.

White Out Cancer™ is a day-long fundraising and awareness event on June 6, 2014, where individuals wear white in support of Cancer Immunotherapy Month™.

more ⇒


White-Out-Cancer campaign of Cancer Research Institute inspires support

On June 6, institutes, companies and citizens around the world are showing their commitment and support for cancer immunotherapy in a campaign initiated by the Cancer Research Institute of New York.

White Out Cancer™ is a day-long fundraising and awareness event on June 6, 2014, where individuals wear white in support of Cancer Immunotherapy Month™.

CIMT staff are wearing white today to increase awareness of cancer immunotherapy, also known as immuno-oncology, as a groundbreaking class of cancer treatment that mobilizes the immune system to fight the disease. CIMT is a collaborator and partner of CRI-CIC in educating the public and enlisting the help of scientists, developers and clinicians around the world to make cancer immunotherapy a routine treatment option for cancer patients.

Learn more about how to participate at: http://www.cancerresearch.org/get-involved/cancer-immunotherapy-month/five-things-you-can-do-right-now/white-out-cancer

Get connected with CIMT on Facebook and Twitter and follow our activities that promote cancer immunotherapy.

Inaugural meeting of new Turkish Society for Immuno-Oncology 04.06.2014

CIMT delegates participated in the inaugural meeting of the newly founded Turkish Society for Immuno-Oncology (IOD) in Antalya, Turkey. The new association was initiated by Prof. Rüchan Uslu and is based in Ankara/Turkey. Its aim is to train medical oncologists through educational and scientific activities in the field of cancer immunotherapy.

 

more ⇒

CIMT delegates participated in the inaugural meeting of the newly founded Turkish Society for Immuno-Oncology (IOD), May 14-18 in Antalya, Turkey. The new association was initiated by Prof. Rüchan Uslu and is based in Ankara/Turkey. Its aim is to train medical oncologists through educational and scientific activities in the field of cancer immunotherapy.

In front of more than 100 participants and government representatives, Sebastian Kreiter, CIMT executive director of science, shared the CIMT experience of creating and running a society to benefit the advancement of cancer immunotherapy in Europe. The CIMT leadership delegates welcomed the founding of IOD and expressed support of its goals to increase awareness of cancer immunotherapeutics in patient care.
For more Turkish language information, please see
http://immuno-onkoloji.org/tr

June is Cancer Immunotherapy Month 02.06.2014

CIMT supports Cancer Immunotherapy Month, an initiative hosted by the Cancer Research Institute (CRI). 

more ⇒

June is Cancer Immunotherapy Month

CIMT supports Cancer Immunotherapy Month, an initiative hosted by the Cancer Research Institute (CRI). With significant support from the biotech and pharmaceutical industry as well as leading academic research hospitals, Cancer Immunotherapy Month is helping accelerate the development of immunotherapies by raising funds to support cancer immunotherapy research, increasing awareness and educating the public, and enlisting the help of scientists and clinicians around the world.

White Out Cancer

Established by the Cancer Research Institute, White Out Cancer™ is a day-long fundraising and awareness event on June 6, 2014, where individuals wear white in support of Cancer Immunotherapy Month™.

 Learn more about how to participate at: http://www.cancerresearch.org/get-involved/cancer-immunotherapy-month/five-things-you-can-do-right-now/white-out-cancer

 


Downloads

Cancer Immunotherapy meets Oncology - A new book on the state of the art in cancer immunology 13.05.2014

Members of the Association for Cancer Immunotherapy have published a comprehensive update on the state of the art in cancer immunology. Honoring the lifetime achievements of CIMT President Christoph Huber, the book covers all key recent developments in immune-oncology.

more ⇒

Members of the Association for Cancer Immunotherapy have published a comprehensive update on the state of the art in cancer immunology. Honoring the lifetime achievements of CIMT President Christoph Huber, the book covers all key recent developments in immune-oncology, from the changing immunological and regulatory frameworks to the most promising therapeutic concepts. More than 50 expert authors discuss themes from combination therapies and personalized medicine, as well as identification of biomarkers to guide the clinical development of new approaches and to pinpoint the optimal treatment for each patient. The book acknowledges the continuing dynamic nature of the field as reflected in the development of next-generation immunotherapies that are already in clinical testing.

The book was presented to Christoph Huber at the 2014 Annual Meeting.

C.M. Britten, S. Kreiter, M. Diken, H.-G. Rammensee (Eds.)
Cancer Immunotherapy Meets Oncology
In Honor of Christoph Huber

Available as printed book or eBook at spoinger.com/shop.

 Special offer  Get 10% off the printed book or eBook!
Use the following token on springer.com
 FhEQFGBCWh2sfDt (Valid 05/07/14 - 06/07/14)


Downloads

The 12th Annual Meeting of the Association for Cancer Immunotherapy attracts record number of participants to Mainz 06.05.2014

The Association for Cancer Immunotherapy (CIMT) today opened its 2014 Annual Meeting "Next Waves in Cancer Immunotherapy” in Mainz, Germany.  This year's meeting, which runs from May 6-8, 2014, brings together more than 850 academic and clinical professionals from over 30 countries, making CIMT the largest European meeting dedicated to the field of cancer immunotherapy.

more ⇒


The 12th Annual Meeting of the Association for Cancer Immunotherapy attracts record number of participants to Mainz

Mainz, Germany, May 6, 2014 - The Association for Cancer Immunotherapy (CIMT) today opened its 2014 Annual Meeting "Next Waves in Cancer Immunotherapy” in Mainz, Germany.  This year's meeting, which runs from May 6-8, 2014, brings together more than 900 academic and clinical professionals from over 30 countries, making CIMT the largest European meeting dedicated to the field of cancer immunotherapy.

The 2014 meeting specifically addresses the integration of science and game-changing new technologies, personalized medicines that are on the verge of entering clinical testing, promising cell therapies, tumor micro-milieu studies that will determine therapeutic options, and synergistic combination therapies. A special session on the field of immunoinformatics addresses data analysis and interpretation, tumor genomics using next generation sequencing, immunogenicity predictions and integrated use in clinical cancer immunotherapy.

CIMT again gives young investigators the opportunity to present their work to a large international audience. Chosen from 319 entries, thirty-eight abstracts are presented as short talks. “Every year, the number of abstracts submitted to CIMT increases, with a significant number of theses abstracts involving on-going trials. This reflects the growing trend towards clinical translation,“ comments Dr. Cedrik Britten, head of the CIMT management board.

Complementing the main session program, the CIMT working groups CIP (CIMT Immunoguiding Program) and CIMT-RRG (Regulatory Research Group) hold sessions and panel discussions. The CIP session focuses on standardized and innovative tools for improving the quality of immunomonitoring, while the RRG session gives attention to the regulatory setting for the translation of scientific knowledge to drug development. Another special focus session is dedicated to trans-national research projects funded by the European Union.

“We are pleased to again welcome many of the most prominent leaders from Europe, America, Asia and Australia to Mainz,” says CIMT President, Prof. Dr. Christoph Huber, of the more than 30 international session speakers to present at CIMT 2014. “We look forward to high-powered discussions on novel cancer diagnostics and potent immunotherapies in all stages of development and are pleased that CIMT counts as one of the most influential meetings in the field worldwide”.

 

Registration for CIMT Endeavour ends April 28 10.04.2014

On May 5 CIMT is holding a business workshop on the translation and commercialization of cancer immunotherapies and diagnostics. The workshop CIMT Endeavour will take place at the Hilton Hotel in Mainz, Germany, on May 5, 2014, 11:30-16:00.
A special discount applies to participants also registered for the CIMT Annual Meeting.

more ⇒

Registration for CIMT Endeavour ends April 28

On May 5 CIMT is holding a business workshop on the translation and commercialization of cancer immunotherapies and diagnostics. The workshop CIMT Endeavour will take place at the Hilton Hotel in Mainz, Germany, on May 5, 2014, 11:30-16:00. The registration fee is 50 EUR and includes a business lunch.
A special discount applies to participants also registered for the CIMT Annual Meeting.
The 2014 workshop will allow company founders and experts to discuss funding initiatives, viable business models and product development. Participants can share and discuss the challenges that European biotech companies face in early, mid and late-stage development.
Click here to access the Endeavour program schedule and workshop registration. The registration deadline will be April 28. Go to http://endeavour.cimt.eu/index.php for more infomation.

CIMT Endeavour 2014 is organized in cooperation with Ci3 and Prefound and supported by a grant from the German Ministry of Education and Research.

Now enrolling labs for 2014 ELISPOT Proficiency Panel 26.03.2014

Beginning in May, Immudex will conduct a new ELISPOT Proficiency Panel as established by CIMT and CRI-CIC. Any laboratory, independent of affiliation, geographic location or area of interest, is invited to participate.

more ⇒

Now enrolling labs for 2014 ELISPOT Proficiency Panel

Beginning in May, Immudex will conduct a new ELISPOT Proficiency Panel as established by CIMT and CRI-CIC. Any laboratory, independent of affiliation, geographic location or area of interest, is invited to participate.
Deadline for registration is April 7, 2014. For registration and more information, go to www.proficiencypanel.com.


Downloads

CIMT satellite symposium at AACR 2014 in San Diego 20.03.2014

On April 8, 2014 CIMT, together with the AACR Cancer Immunology (CIMM) Working Group, sponsors a session on “Deciphering and Modulating T-Cell Specificity in Clinically Effective Antitumor Responses”. The session takes place during the Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

more ⇒

CIMT satellite symposium at AACR 2014 in San Diego

On April 8, 2014 CIMT together with the AACR Cancer Immunology (CIMM) Working Group sponsors a session on “Deciphering and Modulating T-Cell Specificity in Clinically Effective Antitumor Responses”.

The session focuses on modulation and deciphering tumor-specific T cells in clinically active therapies. Currently there are a number of immunotherapeutic approaches delivering clinical success in the treatment of cancer (Adoptive Cell Transfer = ACT, immune modulatory antibodies, vaccines, immune-receptor-engineered lymphocytes), which in fact all are based on naturally occurring or “synthetic/engineered” T cell responses. Good evidence accumulates that tumor-specific T cell responses (mutations, newly expressed antigens, viral antigens) or synthetically-engineered T cell responses (CARs or affinity matured TCs) rather than naturally occurring T cell responses to typically shared tumor-associated antigens may be more potent.
The session takes place 3:00 PM to 5:00 PM at Room 25 at the San Diego Convention Center.

Chairs:
Cedrik M. Britten. BioNTech AG, Mainz, Germany;Sjoerd H. Van Der Burg. Leiden Univ. Medical Ctr., Leiden, Netherlands

3:10 PM - 3:25 PM: Cell therapy targeting unique cancer mutations
 Steven A. Rosenberg. National Cancer Inst., Bethesda, MD

3:30 PM - 3:45 PM: Linking cancer exome to immune therapy
 Pia Kvistborg. Netherlands Cancer Inst., Amsterdam, Netherlands

3:50 PM - 4:05 PM: mRNA based personalized cancer immunotherapy
 Ugur Sahin. BioNTech AG, Mainz, Germany

4:10 PM - 4:25 PM: Chemo-immunotherapy to modulate myeloid cells and boost vaccine efficacy
 Sjoerd H. Van Der Burg. Leiden Univ. Medical Ctr., Leiden, Netherlands

4:30 PM - 4:45 PM: Fine-tuned T cell receptors for cancer immunotherapy
Bent Jakobsen. Immunocore, Abingdon, United Kingdom

 

Early registration for CIMT 2014 ends March 14 10.03.2014

A 10% surcharge on tickets for the CIMT 2014 Annual Meeting will apply for registrations after March 14, 2014. There is still a limited amount of tickets available for the CIMT Social Event which will take place on May 7, 2014. The 2014 CIMT Annual Meeting takes place May 6-8, in Mainz, Germany.

more ⇒

A 10% surcharge on tickets for the CIMT 2014 Annual Meeting will apply for registrations after March 14, 2014. There is still a limited amount of tickets available for the CIMT Social Event which will take place on May 7, 2014. The 2014 CIMT Annual Meeting takes place May 6-8, in Mainz, Germany.

More information about registration and ticket pricing can be found at http://meeting.cimt.eu/register/

"CIMT Endeavour" - call for participation 15.01.2014

On May 5, 2014, CIMT gives innovators the chance to present their business ideas to a panel of renowned experts and investors who will advise them how to strengthen their scientific/ IP position and to develop a strong business model. Submission deadline for business idea entries is February 15, 2014. 

more ⇒

"CIMT Endeavour" - call for participation

On May 5, 2014, CIMT gives innovators the chance to present their business ideas to a panel of renowned experts and investors who will advise them how to strengthen their scientific/ IP position and to develop a strong business model.
Submission deadline for business idea entries is February 15, 2014. For more information, please view the 2014 CIMT Endeavour Flyer and Submission Guidelines or contact CIMT at endeavour@cimt.eu.
CIMT Endeavour 2014 is organized in cooperation with Ci3 and Prefound.

CIMT Endeavour - Preliminary Program
May 5, 11:30 - 16:00, Hilton Hotel, Mainz, Germany,

Session I - Reality check: test your business idea
Young entrepreneurs present their ideas to a panel of renowned experts and investors. See the box on the left on how to apply.
Session II - Implementation: translate your idea into a business
In this session you will get an overview of the tools, methods and mindsets that will help you to be successful in your entrepreneurial endeavors.
You will hear how to:
• recognize business potential
• define your market and identify the exact need
• write a convincing business plan
• present your idea
• finance and market your start-up
Session III - Lessons learned: successful ways to build companies
Established biotech entrepreneurs will share their personal experiences about transforming business ideas into successful founding stories. You will receive very personal insights into the challenges and opportunities of new ventures in times of strong scientific and market competition.

2014 Annual Meeting registration is now open 14.01.2014

Online registration is now open for the 2014 CIMT Annual Meeting in Mainz, Germany, at www.meeting.cimt.eu. Tickets for Europe's largest expert meeting on cancer immunotherapy research and development include admission to all sessions and symposia. Special ticket rates apply.

more ⇒

2014 Annual Meeting registration is now open

Online registration is now open for the 2014 CIMT Annual Meeting in Mainz, Germany, at www.meeting.cimt.eu. Tickets for Europe's largest expert meeting on cancer immunotherapy research and development include admission to all sessions and symposia. Special ticket rates apply.

The 2014 CIMT Annual Meeting will address the integration of science and game-changing new technologies, personalized medicines that are on the verge to enter clinical testing, promising cell therapies, tumor micro-milieu studies that will determine therapeutic options, and synergistic combination therapies.

CIMT expects key discussions on highly potent instruments that expedite the development of novel cancer diagnostics and therapies.

CIMT 2014 will include a special session on immunoinformatics and genomics. The session will address data analysis and interpretation, tumor genomics using next generation sequencing, immunogenicity predictions and integrated use in clinical cancer immunotherapy.

In addition, CIP (CIMT Immunoguiding Program) and CIMT-RRG (Regulatory Research Group) will hold sessions and panel discussions that focus on standardized and innovative tools for improving the quality of immunomonitoring, and the regulatory setting for the translation of scientific knowledge to drug development. The RRG session will specifically address preclinical study design suited for a new class of immunotherapies.

2014 scientific sessions:
Tumor Vaccination, Combination Therapy, Improving Immunity, Immunoguiding, Immunoinformatics and Genomics, Cellular Therapy, Regulatory Research and Tumor Microenvironment

CIMT 2014 - Call for Abstracts 18.12.2013

12th Annual Meeting of the Association for Cancer Immunotherapy
May 6-8, 2014 in Mainz, Germany
Submit your abstract and participate in Europe's largest expert meeting on cancer immunotherapy research and development. Abstract submission deadline is February 28, 2014.

more ⇒

CIMT 2014 - Call for Abstracts

12th Annual Meeting of the Association for Cancer Immunotherapy
"Next Waves in Cancer Immunotherapy"
May 6-8, 2014 in Mainz, Germany

Submit your abstract and participate in Europe's largest expert meeting on cancer immunotherapy research and development. Abstract submission deadline is February 28, 2014.
The abstract committee is calling for abstract submissions in the sub-specialties of:
Therapeutic Vaccination, Immunomonitoring, Cellular Therapy, New Targets & New Leads, Tumor Biology and Interaction with the Immune System, Improving Immunity, Cellular Therapy, New Targets & New Leads
All accepted abstracts will be presented as posters. Selected abstracts will be presented as short talks.
For abstract submission and conference information go to our dedicated meeting page www.meeting.cimt.eu

Now enrolling labs for MHC and ELISPOT Proficiency Panel 31.10.2013

Beginning in November, Immudex will conduct a new MHC Multimer and ELISPOT Proficiency Panel as established by CIMT and CRI-CIC. Any laboratory, independent of affiliation, geographic location or area of interest, is invited to participate.

 

more ⇒

Now enrolling labs for MHC and ELISPOT Proficiency Panel

Beginning in November, Immudex will conduct a new MHC Multimer and ELISPOT Proficiency Panel as established by CIMT and CRI-CIC. Any laboratory, independent of affiliation, geographic location or area of interest, is invited to participate.

Deadline for registration is the week of November 5, 2013. For registration and more information, go to www.proficiencypanel.com.


Downloads

New blueprint outlines a regulatory framework for novel "actively personalized" vaccines ("APVACs) 10.10.2013

CIMT-RRG proposal published in Nature Biotechnology enables the clinical development of personalized therapies

more ⇒

New blueprint outlines a regulatory framework for novel “actively personalized” vaccines (“APVACs”)

CIMT-RRG proposal published in Nature Biotechnology enables the clinical development of personalized therapies

Mainz, Germany, Oct. 10, 2013 – The Regulatory Research Group of the Association for Cancer Immunotherapy (CIMT-RRG) has published a blueprint for the development of actively personalized vaccines (APVACs). The proposal, published in the October issue of Nature Biotechnology, outlines how APVACs may be pursued within the existing regulatory framework of the European Union (EU).

Personalization of cancer treatment has been proposed as a solution to increase the efficacy of novel therapies to treat cancer. The availability of whole genome sequencing enables therapeutic concepts that actively use whole genome data to design tailored vaccines that target the unique genomic alterations found in an individual patient’s tumor. Such “actively personalized vaccines (APVACs)” have not yet been tested in patients. APVAC concepts that lead to unique medicines for every individual patient change the paradigm of how drugs are developed and clinically tested and thus pose a series of regulatory challenges.  The CIMT Regulatory Research Group has analyzed the existing EU regulatory framework and has come to the conclusion that APVACs may be pursued within established principles. A meeting with the Innovation Task Force of the European Medicines Agency (EMA) confirmed the possible path for the development of APVACs as proposed by the CIMT Regulatory Research Group.

“Our publication shows that the specific concepts already in use for cellular therapies may be applicable for individualized therapies,” says Ulrich Kalinke, director of TWINCORE and corresponding author of the paper in Nature Biotechnology. “Even if challenges remain, the first hurdle for clinical testing of this new class of therapies is cleared.”

“This is a milestone publication for the clinical translation of the APVAC concept,” says Cedrik Britten (Ribological GmbH, Mainz), one of the authors of the paper. “Where there had previously not been any regulatory guidance for such actively personalized therapies, we have been able to describe a possible path that will facilitate human testing of individually tailored medicine.”

“I am very pleased that this was an international effort as it would not have been possible for single individuals or institutions,” says Harpreet Singh (Immatics Biotechnologies, Tübingen), also a co-author of the paper. “The results of the Regulatory Research Group pave the way for the future of personalized immunotherapies from which researchers and developers worldwide will benefit.”

Reference:
Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen K-J, Khleif SN, Kreiter S, Nielsen M, Rammensee H-G, Sahin U, Hinz T, Kalinke U (2013): The regulatory landscape for actively personalized cancer immunotherapies, Nature Biotechnology 31 (10), 880-882. doi 10.1038/nbt.2708.


About the Regulatory Research Group (RRG) of the Association for Cancer Immunotherapy (CIMT
Founded in 2008, the CIMT Regulatory Research Group is an independent group of experts from academia and pharmaceutical industry focusing on regulatory aspects of drug development. The group aims to identify the regulatory challenges posed by emerging immunotherapies, to discuss and develop new regulatory concepts that enable the clinical testing of innovative immunotherapies, and to facilitate discussion between all groups relevant for the translation of scientific knowledge from bench top bedside


About the Association for Cancer Immunotherapy (CIMT)
The Association for Cancer Immunotherapy (CIMT) is an international networking  and education platform aiming to facilitate the development of new immunotherapies against cancer for the benefit of patients. CIMT was founded in 2002, and has its home office in Mainz, Germany. The association hosts the largest European expert meetings on cancer immunotherapy, publishes therapeutic guidelines and has established two topic-specific working groups: the CIMT Regulatory Research Party, focusing on the regulatory aspects of drug development, which is pioneering the regulatory framework of actively personalized vaccines for single patient use only; and the CIMT Immunoguiding Program (CIP), which focuses on the quality control and harmonization of immunomonitoring assays. To reach its goals, CIMT closely cooperates with various international partners. Visit www.cimt.eu for more information.


Downloads

Report on the 11th CIMT Annual Meeting 19.09.2013

Published in the September issue of Human Vaccines & Immunotherapeutics, a new meeting report on the 11th CIMT Annual Meeting summarizes the highlights of all lectures presented at the largest cancer immunotherapy meeting in Europe. 

more ⇒

Report on the 11th CIMT Annual Meeting

The report can be accessed at:
https://www.landesbioscience.com/journals/vaccines/2013HV0169.pdf

CIMT at 2013 DGfI Annual Meeting 05.09.2013

At the Annual Meeting of the German Society for Immunology, CIMT presents two workshops and one plenary session dedicated to cancer immunotherapy. The meeting takes place September 11-14 in Mainz, Germany.

more ⇒

CIMT at 2013 DGfI Annual Meeting

At the Annual Meeting of the German Society for Immunology, CIMT presents two workshops and one plenary session dedicated to cancer immunotherapy. The meeting takes place September 11-14 in Mainz, Germany.

September 13:

10:30-12:00        Workshop: antibodies and their targets in cancer therapy
16:00-17:30        Workshop: therapeutic tumor vaccination

September 14:

10:30-12:00        Plenary session: new concepts in cancer immunotherapy

 

  • Linking cancer exomes to cancer immunotherapy

    Ton Schumacher (Amsterdam/The Netherlands)

  • Molecular and metabolic control of adaptive immunity by tumor-induced myelopoiesis

    Vincenzo Bronte (Verona/Italy)

  •  Genomics tailored Cancer Immunotherapy

    Ugur Sahin (Mainz, Germany)

 
For more information about the 2013 DGfI Annual Meeting, go to:
http://www.immunology-conference.de/

New Proficiency Panel of the CIMT Immunoguiding Program (CIP) 17.07.2013

Mainz/Copenhagen, July 17, 2013 – A MHC Multimer and ELISPOT Proficiency Panel will be conducted in October/November 2013 – your chance to test your lab’s proficiency in performing the Elispot and/or Multimer assays.

more ⇒

New Proficiency Panel of the CIMT Immunoguiding Program (CIP)

A MHC Multimer and ELISPOT Proficiency Panel will be conducted in October/November 2013 – your chance to test your lab’s proficiency in performing the Elispot and/or Multimer assays.

Details of the proficiency panels, including an exact date for the shipping to participants of cell samples, will be made available in August.

You may register or get more information at www.proficiencypanel.com  

  • Who can participate?  Any lab with a need to perform reliable immune monitoring can participate.
  • What will happen?  i) Our panel partner Immudex will send out identical and pretested PBMC samples to all participants including instructions,  ii) Each participating lab will perform the assay following their own SOP and report the result back to Immudex,  iii) Each participant will receive a report detailing the participant’s performance. The other participants’ individual performance data will be held confidential.
  • When?  Cell samples will be sent out in October or November.
  • What does it cost to participate?  Participation fee per assay panel is 250 EUR (academia, non-profit organizations), 500 EUR (zero revenue small companies), 700 EUR (positive revenue small companies), and 1000 EUR (pharmaceutical companies). Participation fee includes samples, antigens (Elispot), shipping of cell samples, and the final report.

In the past, CIMT-CIP and the Cancer Immunotherapy Consortium of the Cancer Research Institute (CRI-CIC) and have been in charge of the proficiency panels. Immudex is continuing this service starting with the proficiency panels this fall. Immudex and the two organizations are collaborating tightly in order to ensure a smooth continuation of previous proficiency panels. The proficiency panels continue to be run on a non-profit basis.

If you have questions or comments, please send an email to proficiencypanel@immudex.com


Downloads

EU funded consortium to develop fully personalized cancer vaccines for brain cancer patients 04.07.2013

CIMT one of 14 organizations to collaborate on groundbreaking approach to treating glioblastoma

more ⇒

EU funded consortium to develop fully personalized cancer vaccines for brain cancer patients

A highly innovative project supported by a €6 million European Union Framework 7 (EU FP7) program grant to develop a novel class of therapeutic cancer vaccines is now under way. The Glioma Actively Personalized VAccine Consortium (GAPVAC) is the first EU-funded initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat cancer patients. The consortium consists of 14 organizations from the biotech industry and academia with cutting-edge expertise in cancer vaccine development.

The clinical trial will be accompanied by an extensive biomarker program led by CIMT and immatics to confirm the mechanism-of-action and to identify biomarker signature candidates predicting which patients are most likely to benefit from treatment with APVACs. CIMT will also act as the dissemination platform and will contribute to the biomarker program and regulatory approach through its working parties. In addition, the CIMT Immunoguiding Program (CIP) will coordinate the harmonization of in vitro assays used for monitoring T-cell responses of TILs in vaccinated patients.

“It is a great opportunity for the CIMT Immunoguiding Program to be part of GAPVAC where we can apply our harmonization expertise to tumor infiltrating T cells”, says Cécile Gouttefangeas, chair of CIP. Christoph Huber, chairman of the CIMT Executive Board, adds: “As one of the pioneering associations concerned with the regulatory challenges of actively personalized cancer immunotherapies, CIMT is pleased to collaborate with a consortium which develops a highly innovative, first-in-class treatment for patients suffering from glioblastoma.”

Declaration of Partnership between CIMT and JACI 31.05.2013

CIMT and the Japanese Association for Cancer Immunology (JACI) have entered into a partnership to support each other and share information to further the research and development of cancer immunotherapies worldwide.

more ⇒


Declaration of Partnership between CIMT and JACI

The Association for Cancer Immunotherapy (CIMT) and the Japanese Association for Cancer Immunology (JACI) have entered into a partnership to support each other and share information to further the research and development of cancer immunotherapies worldwide.

Christoph Huber, President of the CIMT Executive Board, and Kyogo Itoh, President of the JACI Executive Board, have signed a document to formalize existing friendships and collaborations.

“We look forward to working more closely together with our Japanese partners who have built a very active community and who share our enthusiasm to collectively advance better therapies for cancer patients,” says Christoph Huber.

The partnership was signed during the CIMT 2013 Annual Meeting in Mainz, Germany.

The 11th Annual Meeting of the Association for Cancer Immunotherapy today opened in Mainz 14.05.2013

More than 670 registered attendees; over 260 scientific abstracts selected for presentation

more ⇒

The 11th Annual Meeting of the Association for Cancer Immunotherapy today opened in Mainz

With the slogan “Advancing Targeted Therapies,” the 2013 Annual Meeting in Mainz again provides a forum for international exchange about new and innovative cancer therapies that monitor and modulate the immune system to actively address cancer. CIMT welcomes more than 720 registered attendees and over 30 international speakers.

This year the scientific program spotlights advanced strategies for targeted immunotherapies. Dedicated sessions on the tumor micro-environment are addressing disease mechanisms and propose strategies to optimize immunotherapies. Exciting recent results combining immunotherapies with other standard cancer treatments are being presented along¬side preclinical and clinical trial results. Sessions on therapeutic vaccination, cellular therapy and improving immunity address recent advances and future applications. In addition, the CIMT Immunoguiding Program (CIP) and the CIMT Regulatory Research Group (RRG) hold discussion sessions focusing on standardized and innovative tools for improving the quality of immunomonito¬ring and facilitating the translation of scientific knowledge to drug development. As every year, CIMT gives young investigators the opportunity to present their work to a large international audience. Chosen from over 260 entries, thirty-six abstracts are presented as short talks.

“By focusing on novel biomarker technologies, personalized medicine concepts and early clinical trials, CIMT is also providing a networking platform for the advancement of immune-oncology discoveries into medical products” says CIMT President Prof. Dr. Christoph Huber. “We are pleased to bring together international opinion leaders from academic institutions, industry and regulatory agencies in one place discuss how to bring better therapies to cancer patients”.

For the first time, CIMT offers a new workshop in which experienced entrepreneurs and experts will discuss translating and developing science into products. Says Dr. Cedrik Britten, CIMT Director Translational Medicine: “It takes tenacity and vast resources to advance scientific innovations into new approved medicines. All aspects of technology commercialization have thus become important, even for translational scientists working at universities and not-for-profit institutes, and we are happy to address these aspects in addition to the scientific program. “

CIMT Endeavour 13.05.2013

A new CIMT activity focusing on the translation and commercialization of cance immunotherapies and diagnostics

more ⇒

CIMT Endeavour

In Cooperation with CI3 (Cluster for Individualized ImmuneIntervention) CIMT presents the first

CIMT Endeavour Workshop
May 13, 2013

Favorite Parkhotel - Mainz, Germany
Karl-Weiser-Str. 1
55131 Mainz

Immudex Takes On International Proficieny Panels Established by CIMT and CIC 23.04.2013

Copenhagen, Denmark, Mainz, Germany, and New York, USA – April 23, 2013

more ⇒


Immudex Takes On International Proficieny Panels Established by CIMT and CIC

Immudex has entered into a strategic agreement with the US Cancer Immunotherapy Consortium (CIC) of the Cancer Research Institute, and the European Association for Cancer Immunotherapy (CIMT), under which Immudex will provide MHC-peptide multimer and Elispot proficiency panel services worldwide.

What would you like to do?

We are commited to the education of scientists and clinicians active in the research and translation of immunotherapies.  We work as a non-profit organization and depend on donations and financial support. Read here on how to get involved or drop us a line.

 

CIMT Working Groups

CIMT

Get the CIMT newsletter

Subscribe to CIMT newsletter